Neogen Corporation logo
Neogen Corporation NEOG
$ 10.34 3.61%

Quarterly report 2025-Q4
added 01-08-2026

report update icon

Neogen Corporation Financial Ratios 2011-2026 | NEOG

Annual Financial Ratios Neogen Corporation

2025 2024 2023 2022 2021 2020 2019 2018 2017 2016 2015 2014 2013 2012 2011

P/E

-0.9 -404.0 -196.9 50.8 63.8 70.7 53.9 65.7 60.3 57.8 52.6 52.8 49.2 48.5 45.6

P/S

1.1 4.1 5.5 4.7 8.3 10.1 7.8 10.3 7.3 6.6 6.2 6.0 6.4 5.9 6.0

EPS

-5.0 -0.0 -0.1 0.5 0.6 0.6 0.6 1.2 0.9 0.7 0.9 0.8 0.8 0.6 1.0

EV (Enterprise Value)

2.26 B 5.04 B 5.76 B 2.51 B 3.89 B 4.21 B 3.26 B 4.12 B 2.62 B 2.11 B 1.74 B 1.49 B 1.32 B 1.08 B 1.04 B

EBITDA per Share

-4.34 0.81 0.67 0.76 0.89 0.82 0.821 0.843 0.782 0.688 0.644 0.537 0.5 0.422 0.447

EV/EBITDA

40.3 47.0 37.3 46.6 32.2 29.9 26.6 27.5 26.7 26.1 24.4

PEG

0.01 -699.71 47.62 -262.41 11.7 13.83 -9.66 1.57 3.39 7.42 2.95 30.48 2.65 -13.02 1.64

P/B

0.5 1.2 1.4 2.8 4.6 5.8 5.1 7.4 5.6 5.2 5.0 4.9 5.2 5.0 5.5

P/CF

17.5 107.9 109.8 36.0 47.9 49.0 65.9 86.1 57.8 100.1 51.6 146.9 75.7 110.7 49.4

ROE %

-52.72 -0.30 -0.73 5.44 7.24 8.20 9.43 11.27 9.29 9.05 9.55 9.19 10.53 10.29 12.11

ROA %

-31.71 -0.21 -0.50 4.87 6.62 7.46 8.65 10.22 8.29 8.09 8.55 8.15 9.36 8.95 10.40

ROCE %

-51.22 1.87 1.20 6.61 8.83 9.31 10.36 12.12 13.19 13.33 14.48 13.55 14.92 14.57 17.75

Current Ratio

2.5 3.2 3.2 9.4 11.5 11.1 11.8 9.7 8.1 8.7 9.1 7.6 9.5 7.2 6.9

DSO

66.6 64.4 56.1 66.3 68.8 73.0 72.8 71.8 69.2 76.9 76.3 76.6 68.1 70.7 60.5

DIO

146.6 128.1 112.2 143.2 141.0 148.9 141.2 130.9 140.8 139.7 131.4 149.7 142.7 139.4 137.6

DPO

62.7 63.3 48.8 37.6 35.7 36.8 31.3 35.7 31.3 34.3 34.9 39.2 34.3 42.9 36.6

Operating Cycle

213.2 192.5 168.3 209.5 209.7 221.9 214.0 202.6 210.0 216.5 207.7 226.2 210.8 210.1 198.1

Cash Conversion Cycle

150.4 129.2 119.6 171.9 174.1 185.1 182.7 166.9 178.7 182.3 172.8 187.1 176.5 167.2 161.5

All numbers in USD currency

Quarterly Financial Ratios Neogen Corporation

2025-Q4 2025-Q3 2025-Q2 2025-Q1 2024-Q4 2024-Q3 2024-Q2 2024-Q1 2023-Q4 2023-Q3 2023-Q2 2023-Q1 2022-Q4 2022-Q3 2022-Q2 2022-Q1 2021-Q4 2021-Q3 2021-Q2 2021-Q1 2020-Q4 2020-Q3 2020-Q2 2020-Q1 2019-Q4 2019-Q3 2019-Q2 2019-Q1 2018-Q4 2018-Q3 2018-Q2 2018-Q1 2017-Q4 2017-Q3 2017-Q2 2017-Q1 2016-Q4 2016-Q3 2016-Q2 2016-Q1 2015-Q4 2015-Q3 2015-Q2 2015-Q1 2014-Q4 2014-Q3 2014-Q2 2014-Q1 2013-Q4 2013-Q3 2013-Q2 2013-Q1 2012-Q4 2012-Q3 2012-Q2 2012-Q1 2011-Q4 2011-Q3 2011-Q2 2011-Q1

EPS

-0.07 0.17 - -0.05 -2.1 -0.06 - -0.01 -0.02 0.01 - 0.04 -0.19 0.05 -0.23 0.05 0.1 0.16 0.26 0.13 0.15 0.15 0.3 0.12 0.15 0.14 0.31 0.28 0.31 0.29 0.31 0.29 0.33 0.23 0.33 0.31 0.22 0.2 0.29 0.26 0.24 0.25 0.24 0.25 0.21 0.24 0.21 0.24 0.17 0.22 0.17 0.33 0.19 0.19 0.29 0.28 0.22 0.26 0.22 0.26

EBITDA per Share

- 0.06 - - - 0.15 - 0.16 0.18 0.22 - 0.18 0.07 0.11 0.29 0.08 0.14 0.26 0.43 0.15 0.18 0.22 0.54 0.25 0.35 0.4 0.52 0.4 0.35 0.4 0.52 0.4 0.35 0.4 0.51 0.53 0.33 0.48 0.63 0.48 0.39 0.47 0.54 0.33 0.35 0.43 0.49 0.43 0.27 0.4 0.38 0.6 0.29 0.5 0.58 0.5 0.35 0.46 0.47 0.46

ROE %

0.13 -16.20 -17.91 -17.97 -17.63 -0.64 -0.13 0.13 0.46 -0.78 -0.50 -4.62 -4.26 -1.67 -0.26 7.19 8.16 8.95 9.07 7.94 8.06 8.37 8.48 8.84 9.42 9.73 10.13 10.45 10.87 11.49 11.32 12.08 11.88 11.16 11.09 10.22 10.14 9.99 10.16 9.99 10.20 10.17 10.43 10.39 10.64 10.44 10.54 10.40 10.54 11.19 11.23 11.93 11.96 11.69 11.81 11.49 11.60 3.06 2.78 3.18

ROA %

0.06 -10.72 -11.81 -11.85 -11.62 -0.44 -0.09 0.09 0.32 -0.52 -0.20 -3.89 -3.52 -1.48 -0.18 6.54 7.44 8.20 8.30 7.14 7.26 7.55 7.66 7.95 8.40 8.66 9.01 9.27 9.61 10.13 9.93 10.44 10.24 9.58 9.52 8.86 8.79 8.65 8.81 8.66 8.82 8.82 9.04 9.04 9.25 9.05 9.10 8.91 8.97 9.55 9.58 10.16 10.19 9.90 9.97 9.68 9.75 2.64 2.23 2.64

ROCE %

- - - - - - - - -0.25 -0.49 0.19 0.26 0.99 2.68 4.53 8.78 9.93 10.97 10.94 9.52 9.48 9.64 9.59 9.80 10.52 10.91 11.28 11.67 12.06 12.49 13.03 13.59 14.13 14.55 14.71 15.06 15.08 14.91 15.27 15.09 14.90 14.97 15.11 15.15 16.03 15.52 15.84 15.37 15.72 16.63 16.55 17.53 17.44 17.04 17.24 16.75 16.93 4.47 4.04 4.64

Current Ratio

2.7 2.7 2.5 2.9 2.9 3.3 3.2 3.2 3.2 3.2 3.2 3.3 3.1 10.4 9.4 9.3 9.6 12.2 11.5 11.5 12.4 11.7 11.7 12.6 12.6 11.8 13.0 12.5 11.3 10.8 11.4 11.1 9.6 9.1 10.3 9.7 9.3 9.1 10.6 9.8 8.9 9.4 10.3 9.9 9.3 9.2 9.4 9.2 8.4 8.2 9.9 9.6 8.4 8.3 8.3 8.0 7.5 7.3 7.6 7.4

DSO

54.9 63.6 - 66.9 65.5 71.6 - 64.6 57.3 58.0 - 60.4 46.8 66.5 24.3 66.0 62.9 63.7 32.4 67.1 62.5 67.8 65.6 75.9 69.6 72.7 69.9 74.2 68.3 72.0 67.4 73.2 63.3 64.6 31.8 68.9 62.5 69.3 68.0 68.3 66.8 72.1 67.9 67.8 69.2 69.9 69.2 65.9 68.5 64.2 59.3 59.5 67.7 67.3 64.1 62.0 65.6 61.2 58.2 -

DIO

137.7 153.5 - 166.4 153.5 157.9 - 139.8 121.8 111.6 - 115.8 103.0 163.6 57.3 142.0 136.5 135.5 66.5 140.2 140.4 148.9 136.1 146.9 139.9 148.9 138.2 141.8 126.5 133.5 121.5 135.6 127.8 135.4 65.5 139.1 137.0 141.9 124.6 133.0 129.6 132.6 113.8 138.2 144.7 144.6 136.4 134.1 138.0 132.9 116.1 124.2 142.9 137.5 - - - - - -

DPO

54.0 62.4 - 62.6 54.6 58.9 - 82.3 81.8 67.8 - 57.8 41.3 40.1 14.2 37.2 37.0 30.9 15.8 32.4 31.9 37.2 33.0 32.3 30.5 32.1 30.6 34.0 33.1 35.9 33.2 34.6 29.6 30.4 14.5 32.2 34.1 35.7 30.6 38.6 39.1 35.0 30.2 32.9 32.4 35.9 35.7 33.7 34.9 33.8 27.9 28.5 34.6 39.5 - - - - - -

Operating Cycle

192.6 217.2 - 233.3 219.0 229.6 - 204.4 179.0 169.6 - 176.2 149.7 230.1 81.6 208.0 199.3 199.2 98.8 207.4 202.9 216.7 201.7 222.8 209.5 221.6 208.1 216.0 194.8 205.5 188.9 208.9 191.0 200.0 97.2 208.0 199.5 211.1 192.7 201.3 196.5 204.6 181.6 206.0 213.8 214.6 205.5 200.0 206.5 197.1 175.4 183.6 210.6 204.8 64.1 62.0 65.6 61.2 58.2 -

Cash Conversion Cycle

138.6 154.8 - 170.7 164.4 170.7 - 122.1 97.2 101.7 - 118.4 108.5 190.0 67.4 170.8 162.4 168.2 83.1 175.0 171.0 179.4 168.7 190.6 179.0 189.5 177.5 182.0 161.7 169.6 155.7 174.3 161.4 169.6 82.7 175.8 165.4 175.4 162.1 162.8 157.4 169.6 151.4 173.1 181.4 178.6 169.8 166.3 171.6 163.3 147.5 155.1 176.0 165.3 64.1 62.0 65.6 61.2 58.2 -

All numbers in USD currency

Multiples are an important financial analysis tool for the company Neogen Corporation, allowing investors and analysts to quickly assess the company’s value and investment attractiveness based on the ratio of market indicators to the company’s financial performance. Essentially, multiples express how the market values the company relative to its earnings, revenue, equity, or other key metrics.

Advantages of Using Financial Ratios
  • Simplified Data Analysis
    Financial ratios transform large volumes of accounting data into compact and easily interpretable indicators, significantly simplifying the assessment of the company’s condition.
  • Comparability Between Companies
    Multiples standardize financial metrics, enabling objective comparison of companies of different sizes, industries, and market capitalizations.
  • Identification of Trends and Issues
    Regular analysis of ratios helps track the dynamics of financial health, identify strengths and weaknesses of the business, as well as potential risks.
  • Decision Support
    Financial multiples serve as an important tool for investors, creditors, and company management in making investment, credit, and managerial decisions.
  • Accelerated Assessment of Investment Attractiveness
    Ratios allow quick determination of key performance, liquidity, and financial stability indicators, facilitating prompt evaluation of companies’ attractiveness for investments.

Using multiples enables comparison between companies, even if they differ in size or industry, as they standardize financial data into ratios convenient for analysis. This is especially useful for evaluating companies where direct analysis of financial statements may be complex or require in-depth knowledge.

Financial Ratios of other stocks in the Diagnostics research industry

Issuer Price % 24h Market Cap Country
Centogene N.V. Centogene N.V.
CNTG
- -6.23 % $ 30.6 M germanyGermany
Agilent Technologies Agilent Technologies
A
$ 116.92 2.67 % $ 35.5 B usaUSA
Aspira Women's Health Aspira Women's Health
AWH
- -6.19 % $ 10.5 M usaUSA
Biocept Biocept
BIOC
- -13.05 % $ 7.29 M usaUSA
BioNano Genomics BioNano Genomics
BNGO
$ 1.18 0.85 % $ 6.43 M usaUSA
Chembio Diagnostics Chembio Diagnostics
CEMI
- 0.22 % $ 16.8 M usaUSA
Enzo Biochem Enzo Biochem
ENZ
- -8.98 % $ 14.8 K usaUSA
DermTech DermTech
DMTK
- -11.32 % $ 2.94 M usaUSA
CareDx, Inc CareDx, Inc
CDNA
$ 17.92 1.41 % $ 955 M usaUSA
Exact Sciences Corporation Exact Sciences Corporation
EXAS
- - $ 19.8 B usaUSA
Oxford Immunotec Global PLC Oxford Immunotec Global PLC
OXFD
- - $ 562 M britainBritain
Akumin Akumin
AKU
- -17.87 % $ 25.9 M canadaCanada
Burning Rock Biotech Limited Burning Rock Biotech Limited
BNR
$ 16.24 0.93 % $ 175 M chinaChina
Co-Diagnostics Co-Diagnostics
CODX
$ 4.4 101.83 % $ 5.85 M usaUSA
Heska Corporation Heska Corporation
HSKA
- - $ 1.31 B usaUSA
HTG Molecular Diagnostics HTG Molecular Diagnostics
HTGM
- -20.0 % $ 1.06 M usaUSA
Interpace Biosciences Interpace Biosciences
IDXG
$ 1.98 -0.63 % $ 8.76 M usaUSA
Illumina Illumina
ILMN
$ 128.0 1.23 % $ 20.4 B usaUSA
Accelerate Diagnostics Accelerate Diagnostics
AXDX
- -61.36 % $ 2.46 M usaUSA
Castle Biosciences Castle Biosciences
CSTL
$ 25.19 1.45 % $ 700 M usaUSA
Global Cord Blood Corporation Global Cord Blood Corporation
CO
- - $ 399 M chinaChina
Fluidigm Corporation Fluidigm Corporation
FLDM
- 1.08 % $ 308 M usaUSA
Genetic Technologies Limited Genetic Technologies Limited
GENE
- - $ 7.1 B australiaAustralia
Genetron Holdings Limited Genetron Holdings Limited
GTH
- 0.12 % $ 80.1 M chinaChina
Laboratory Corporation of America Holdings Laboratory Corporation of America Holdings
LH
$ 274.72 2.06 % $ 22.9 B usaUSA
Charles River Laboratories International Charles River Laboratories International
CRL
$ 175.07 3.26 % $ 8.68 B usaUSA
PRA Health Sciences, Inc. PRA Health Sciences, Inc.
PRAH
- - $ 10.7 B usaUSA
Medpace Holdings Medpace Holdings
MEDP
$ 520.65 2.39 % $ 15 B usaUSA
Danaher Corporation Danaher Corporation
DHR
$ 196.19 2.71 % $ 140 B usaUSA
Motus GI Holdings Motus GI Holdings
MOTS
- -34.28 % $ 263 K israelIsrael
Myriad Genetics Myriad Genetics
MYGN
$ 4.77 0.63 % $ 442 M usaUSA
National Research Corporation National Research Corporation
NRC
$ 17.26 1.29 % $ 386 M usaUSA
Natera Natera
NTRA
$ 210.83 0.75 % $ 20.7 B usaUSA
Invitae Corporation Invitae Corporation
NVTA
- - $ 21.2 M usaUSA
Organovo Holdings Organovo Holdings
ONVO
- -2.3 % $ 19.4 M usaUSA
OpGen OpGen
OPGN
- -16.95 % $ 1.54 M usaUSA
Fulgent Genetics Fulgent Genetics
FLGT
$ 15.83 -0.5 % $ 479 M usaUSA
Pacific Biosciences of California Pacific Biosciences of California
PACB
$ 1.47 2.08 % $ 441 M usaUSA
Guardant Health Guardant Health
GH
$ 92.84 -0.49 % $ 11.6 B usaUSA
PerkinElmer PerkinElmer
PKI
- -0.91 % $ 14.7 B usaUSA
QIAGEN N.V. QIAGEN N.V.
QGEN
- - $ 10.6 B niderlandNiderland
Psychemedics Corporation Psychemedics Corporation
PMD
- -1.84 % $ 15.3 M usaUSA
Personalis Personalis
PSNL
$ 6.33 2.59 % $ 375 M usaUSA
Anixa Biosciences Anixa Biosciences
ANIX
$ 2.73 1.49 % $ 88.6 K usaUSA
Biomerica Biomerica
BMRA
$ 2.15 -0.46 % $ 4.94 M usaUSA
Quotient Limited Quotient Limited
QTNT
- -11.32 % $ 1.1 M schweizSchweiz
ICON Public Limited Company ICON Public Limited Company
ICLR
$ 106.54 -0.58 % $ 8.79 B irlandaIrlanda
Check-Cap Ltd. Check-Cap Ltd.
CHEK
- - $ 9.42 M israelIsrael
Celcuity Celcuity
CELC
$ 116.94 1.19 % $ 5.47 B usaUSA